Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Trial Profile

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms BeyoND
  • Sponsors NeuroDerm
  • Most Recent Events

    • 14 Mar 2024 According to a NeuroDerm media release, analyses of results from the ongoing BouNDless trial complement the long-term safety data from the BeyoND study (NCT02726386) including patients in their eighth year of follow-up.
    • 05 Mar 2024 According to a Mitsubishi Tanabe Pharma America Media release, the company will present a posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal, and virtually, from March 5-9
    • 28 Aug 2023 According to a Mitsubishi Tanabe Pharma America Media release, results from this study will be shared at the International Congress of Parkinson's Disease and Movement Disorder Society (MDS), being held in Copenhagen, Denmark, August 27-31.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top